American Century Companies Inc. Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

American Century Companies Inc. cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 16.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 449,193 shares of the pharmaceutical company’s stock after selling 88,939 shares during the period. American Century Companies Inc. owned approximately 0.18% of Vertex Pharmaceuticals worth $175,922,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Vertex Pharmaceuticals by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock valued at $9,484,293,000 after purchasing an additional 243,088 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Vertex Pharmaceuticals by 2.9% during the second quarter. Geode Capital Management LLC now owns 5,928,747 shares of the pharmaceutical company’s stock worth $2,627,135,000 after buying an additional 166,987 shares during the period. Alliancebernstein L.P. boosted its position in shares of Vertex Pharmaceuticals by 10.7% during the second quarter. Alliancebernstein L.P. now owns 4,378,320 shares of the pharmaceutical company’s stock worth $1,949,228,000 after buying an additional 424,808 shares during the period. Loomis Sayles & Co. L P grew its stake in shares of Vertex Pharmaceuticals by 1.7% in the second quarter. Loomis Sayles & Co. L P now owns 3,813,378 shares of the pharmaceutical company’s stock valued at $1,697,716,000 after buying an additional 65,047 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $1,593,974,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Wall Street Analyst Weigh In

A number of brokerages recently commented on VRTX. Evercore raised their target price on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Morgan Stanley reissued an “overweight” rating and set a $570.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Scotiabank lifted their price objective on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Wells Fargo & Company upped their target price on shares of Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 4th. Twenty-two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $542.00.

Insider Activity

In other news, EVP Jonathan Biller sold 945 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $459,600.75. Following the completion of the sale, the executive vice president owned 13,659 shares in the company, valued at approximately $6,643,054.65. The trade was a 6.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Duncan Mckechnie sold 4,910 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the completion of the transaction, the executive vice president owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 168,937 shares of company stock valued at $77,879,922 over the last 90 days. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 3.5%

Shares of VRTX stock opened at $496.83 on Friday. The firm has a fifty day moving average price of $466.55 and a 200 day moving average price of $432.29. The company has a market cap of $126.21 billion, a P/E ratio of 32.41 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.98 earnings per share. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.